Five things: BIO in Boston, 'Loganing,' Petri Dish and Best Places to Work rankings
1. Forget 'Storrowing.' Massport deals with 'Loganing'
MassPort is taking steps to address an uptick in "too-tall" truck strikes on road signs and overpasses at Logan International Airport, Isabel Hart reports.
GET TO KNOW YOUR CITY
Find Local Events Near You
Connect with a community of local professionals.
Explore All Events
2. BIO is nigh upon us
BIO International, the global convention for life sciences companies, investors, partners and the state and national economic development officials wooing them, is arriving in Boston starting on Monday. Hannah Green has all you need to know about what it means to host this major trade show, and spoke with one of the original architects of the Massachusetts life sciences industry.
3. Alnylam, GSK, Vertex pledge Mass. jobs for tax incentives
Green also reports that 33 life sciences companies are slated to receive $29.9 million in tax incentives in exchange for creating over 1,500 new jobs in Massachusetts.
Do you like the Five Things? Make sure to subscribe — free — to our Morning Edition emails so you have it in your inbox each day.
4. Boston vaccine developer acquired for $1.25B
And because she's not busy enough, Green also reports that CureVac NV, whose U.S. headquarters is in Boston, is being acquired by BioNTech in a deal valued at $1.25 billion.
5. How small businesses can use AI
Small businesses are learning to put AI to work as an extra pair of hands through a partnership with a local nonprofit led by a Boston University researcher and the Black Economic Council of Massachusetts, Eli Chavez reports.
What else you need to know
By the numbers
The Petri Dish
A spinout from Scorpion Therapeutics debuted with $177 million, Bicara Therapeutics doubled its footprint, and the Mass. Life Sciences Center gave out health equity awards of $50,000 — all in the latest biotech news roundup from Hannah Green.
On the radio
This morning at 6:45 or 8:45 on GBH Radio's "Morning Edition" you can hear Jess Aloe report the "Boston Business Journal Minute" — a quick highlight of the week's top stories. Not near the radio? Listen here anytime.
Listen this Sunday to the New England Business Report, where I will be discussing the news of the week with Kim Carrigan and Joe Shortsleeve. Tune in at 8 a.m. on WRKO-AM 680 or listen here.
Quotable
'I feel like the grandmother who sits at the soccer game, and I look out there and I see my little grandchild running up and down the field and scoring goals and being a star player. And nobody knows that that's my grandchild, but I know.' — Susan Windham-Bannister, former head of the Mass. Life Sciences Center, reflecting on the growth of the industry since 2008.
Today in history
On this day in 1995, Alanis Morissette released her breakthrough album, Jagged Little Pill. (On This Day In Music)
Birds I'm seeing
Tree Swallow in Belle Isle Marsh, East Boston
What's good on WERS-FM
Brilliant Mistake, by Elvis Costello
What I'm watching
Kaos, on Netflix
Welcome to the jungle
Whether you like Guns N' Roses, or not, you couldn't ignore the jungle theme at last night's 23rd annual Boston Business Journal Best Places to Work ceremony and reception. Stay tuned for photos from the event, which will be posted to our site later today, but for those of you wondering which companies ranked highest in their size category, you can find all the 2025 Best Places to Work here or scroll below for the rankings themselves.
As I mentioned, the event was 'jungle-themed,' meaning lots of vegetation, animals and reptiles, stilt-walking giraffes, elephants and lions, and more. We had over 300 nominations this year, and from those, Massachusetts-based employees were surveyed by Quantum Workplace, our longtime data partner, and their responses led us to expand this year's ranking from 80 companies to 100 qualifying as Best Places to Work.
If you love your company and think it could be among the top-ranked Best Places to Work, be sure to contact Sean McFadden, our associate editor, research, who will make sure you're included in the survey process next year.
PARTING SHOT
You know how much I love a wildlife webcam. Well, these researchers are using hidden cameras in the jungles of Central America to get help from the animals themselves in documenting the rainforest's incredible variety of species.
Subscribe to the Morning Edition or Afternoon Edition for the business news you need to know, all free.
Best Places to Work: Extra Large Companies (500 employees and up)
Score
Rank Prior Rank Company
1
1
VHB
2
6
Arbella Insurance Group
3
3
Vertex Pharmaceuticals Inc. View this list
Best Places to Work: Large Companies (250 to 499 employees)
Score
Rank Prior Rank Company
1
2
Wasabi Technologies
2
2
CyberArk
3
3
Weston & Sampson View this list
Best Places to Work: Medium Companies (100 to 249 employees)
Score
Rank Prior Rank Company
1
1
SEI - Boston
2
2
RapDev LLC
3
2
J. Calnan & Associates View this list
Best Places to Work: Small Companies (50 to 99 employees)
Score
Rank Prior Rank Company
1
1
Tines
2
3
Ligris + Associates PC
3
3
Your Part-Time Controller LLC View this list
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Google packs new Pixel phones with AI
Google on Wednesday unveiled new Pixel 10 smartphones, showcasing artificial intelligence (AI) capabilities woven into its Android mobile operating system. The line-up of new products included a foldable phone, improved Pixel smartwatch, and ear buds all synced to work with AI and each other. "Pixel continues to be the best way for people to try out the latest bleeding-edge AI from Google," product manager Tyler Kugler said during a briefing with journalists. Pixel phones claim a scant portion of a high-end smartphone market ruled by Apple, Samsung and Xiaomi, but custom Google hardware is an opportunity for the internet giant to highlight what is possible with its Android mobile operating system. And while Samsung routinely ranks as the world's top smartphone seller, it powers handsets with Android software from Google. "Initially, Google Pixel devices were designed as a technological showcase to limit Android fragmentation and accelerate innovation," said Forrester principal analyst Thomas Husson. "Ten years later, the strategic challenge is still not to become the market leader, but to demonstrate the value of Google's integrated ecosystem." The tactic promises to promote use of Google's platform by handset makers and is a spin on the way Apple ties together its iPhones and other devices with its software. Meanwhile, with Apple seen as lagging in the fierce AI race, Google has touted all-out efforts to integrate advanced AI throughout its offerings as it competes with powerhouses such as Amazon, Meta, and Microsoft. "Its positioning remains premium and its market share is less than 5 percent, but in the age of AI, it is a true laboratory of innovation," Husson said of the Pixel smartphone line. It is also "a means of countering Apple's integrated hardware-software-services strategy while remaining a strategic partner for Samsung and the Android ecosystem," Husson added. AI built into new Pixel phones lets Gemini AI assistant look through the cameras to "see" what users see, answering questions or providing tips about locations, objects or situations, according to Kugler. Google is not the only one putting AI in phones. South Korean consumer electronics giant Samsung has made AI a centerpiece of its Galaxy smartphone line and recently released a new Galaxy Z Fold7. Google's product team described the new Pixel Watch 4 as a redesigned experience that marks the biggest update to the line. Features include smartwatch fitness tracking fine-tuned to distinguish between activities such as walking, bicycling, or tennis. The Pixel Watch also enables users to command Gemini AI assistant from one's wrist. Gemini detects the mood of whoever is speaking to it and adjusts its responses accordingly, and can even "look" through the phone camera to offer photo suggestions, according to the Google team. gc-juj/ksb Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
Human Osteoblasts Market to Reach US$ 87.1 Million by 2033
The market is currently experiencing robust growth, fueled by a post-pandemic surge in orthopedic surgeries and significant investment in regenerative medicine. Innovations in 3D bioprinting and smart scaffolds are creating new therapeutic possibilities for bone repair. Chicago, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global human osteoblasts market was valued at US$ 48.2 million in 2024 and is expected to reach US$ 87.1 million by 2033 at a CAGR of 6.8% during the forecast period 2025–2033. The future potential of the human osteoblasts market lies in the convergence of artificial intelligence with advanced biomanufacturing. AI-powered platforms are now capable of analyzing genomic data from 1000s of individuals to predict osteoblast response to new drug compounds, drastically reducing discovery timelines. This synergy is enabling the creation of patient-specific 3D-bioprinted bone grafts. As of 2025, researchers are successfully embedding patient-derived osteoblasts into custom scaffolds with 95% cell viability post-printing. These constructs are being tested in preclinical models for craniofacial reconstruction and spinal fusion, promising a new era of personalized regenerative medicine. Demand for highly characterized osteoblasts for these applications is projected to soar. Download Sample Pages: Another significant growth frontier of the human osteoblasts market is the application of osteoblast research to counteract microgravity-induced bone loss in astronauts. With 3 new long-duration space missions planned by international agencies before 2028, research into osteoblast function in simulated microgravity is intensifying. Furthermore, the veterinary orthopedics market represents a substantial, untapped opportunity. In 2024, an estimated 1.2 million companion animals in the U.S. alone underwent procedures for fractures or degenerative joint diseases. The development of canine and equine osteoblast cell lines for testing new veterinary implants and cell-based therapies is an emerging field that could create an entirely new vertical within the broader market. Key Findings in Human Osteoblasts Market Market Forecast (2033) US$ 87.1 million CAGR 6.8% Top Drivers Rising prevalence of osteoporosis and degenerative bone diseases globally. Technological advancements in cell-based therapies and tissue engineering. Increasing geriatric population driving demand for orthopedic surgical procedures. Top Trends Shift towards personalized medicine using patient-derived osteoblast cultures. Development of 3D bioprinting for creating patient-specific bone grafts. Growing adoption of minimally invasive bone regeneration surgical techniques. Top Challenges Expensive cell-based therapies and procedures. Stringent and complex regulatory approval pathways for new biologics. Top 12 Key Players Strategically Dominate the Evolving Global Human Osteoblasts Market The competitive environment is both concentrated and highly specialized. Analysis in 2024 consistently identifies 12 key players shaping the industry. These include Sigma-Aldrich, Athersys Inc., Cerapedics Inc., CryoLife, Inc., and Cytori Therapeutics Inc. Other notable companies are USA Stem Cell Inc., Vericel Corporation, Wright Medical Group N.V, Biocomposites, BD, Zimmer Biomet, and PromoCell. In the crucial U.S. orthopedic biomaterials sector, a key application area, 3 major competitors—Medtronic, DePuy Synthes, and Stryker—were noted as dominant forces in 2024. Suppliers offer highly specific product lines to meet diverse research needs. As of 2025, PromoCell provides 4 primary product categories related to osteoblasts, including cells and specialized growth media. Similarly, Innoprot offers 2 distinct types of primary human osteoblasts as of 2024 Human Calvarial and Human Femoral Osteoblasts in the human osteoblasts market. InSCREENex provides 1 specific immortalized human osteoblast cell line, CI-huOB. Product quality and performance are paramount. Lonza guarantees 10 population doublings for its Clonetics™ Normal Human Osteoblasts, ensuring robust expansion for 2024 research. Innoprot's immortalized cells demonstrate a growth potential of over 30+ passages, a significant advantage. Recent Product and Technology Launches Signal Rapid Advancement Within the Market Innovation remains a cornerstone of human osteoblasts market growth, with companies actively launching advanced products. On April 15, 2024, CryoLife, Inc. introduced 1 new osteoblast culture system designed to enhance cell viability. Zimmer Biomet followed suit in February 2024, launching 1 new bioreactor system for osteoblast cultivation with improved scalability. Innovation extends to cell preservation. In 2024, PromoCell released 1 new protein- and animal component-free cryopreservation medium, Cryo-SFM Plus, featuring advanced antioxidant technology. Intellectual property is also a key competitive tool. Bone Solutions Inc. was awarded 5 new patents in fiscal year 2025 for its Mg OSTEOCRETE technology, a bone substitute that stimulates osteoblast activity. Practical usability is crucial for clinical adoption. Bone Solutions' Mg OSTEOCRETE boasts a preparation time of just 30 seconds, a significant handling benefit for 2025 applications. To support adjacent research fields, PromoCell also launched 1 new Cancer Media Toolbox in 2024 to facilitate the establishment of primary cancer cell lines and complex 3D tumor models. Active Clinical Trials for Osteoblast-Related Therapies Underpin Future Market Expansion The clinical development pipeline is a strong indicator of future commercial opportunities. In February 2024, Biocomposites initiated 2 Phase 2 clinical trials for its STIMULAN VG® bone graft substitute. These trials will assess efficacy in treating diabetic foot osteomyelitis and stage 4 pressure ulcers. Osteosarcoma research, a critical area for the human osteoblasts market, is also advancing. In 2024, the Osteosarcoma Institute (OSI) sponsored 1 Phase 2 clinical trial in Spain for OMO-103, a promising MYC inhibitor. A remarkable 25 months was the fast-tracked timeline to launch the OMO-103 trial, showcasing increased efficiency in clinical development. In the United States, a 2024 study was published on 1 FDA/IRB-approved GMP-manufactured stem cell product, PSC-01, for knee osteoarthritis. The study showed that a single treatment provided pain reduction and increased function for 2.5 years. Research methodologies are also being refined. A 2024 clinical trial enrolled 30 patients to analyze the effects of lasers on alveolar bone preservation. A Phase 1 trial protocol published in 2024 detailed a 3+3 dose escalation method for a study using human umbilical cord-derived osteoblasts for femoral head osteonecrosis. Favorable Regulatory Approvals in 2024 Create a Promising Outlook for Therapies The regulatory climate for cell and gene therapies in the human osteoblasts market became increasingly favorable in 2024. The FDA approved 7 new cell and gene therapy products Amtagvi, Aucatzyl, Beqvez, Kebilidi, Ryoncil, Symvess, and Tecelra. The pace of approvals is accelerating, with 3 of these therapies gaining approval in early 2024 alone. On December 19, 2024, the FDA approved 1 mesenchymal stem cell product, Ryoncil from Mesoblast. Another landmark approval was granted on November 13, 2024, for 1 gene therapy for AADC deficiency, Kebilidi from PTC Therapeutics. On November 8, 2024, the FDA approved 1 CD19-directed T-cell immunotherapy, obecabtagene autoleucel (Aucatzyl), from Autolus Inc. The recommended dose for Aucatzyl is 410x10^6 CAR-positive viable T-cells. StemCyte received approval for 1 allogeneic hematopoietic stem cell therapy, Regenecyte, on November 26, 2024. Patent activity, a precursor to commercialization, is also strong. Innovators at the University of Pittsburgh were issued 5 patents in August 2024, while University of Minnesota researchers secured 111 US patents in 2024 for various health science discoveries. Significant Funding and Strategic Grants Accelerate Osteoblast-Focused Research and Development Robust financial investment is fueling the engine of scientific discovery across the global human osteoblasts market. The Osteosarcoma Institute (OSI) awarded $1,100,000 to 3 groundbreaking osteosarcoma research projects during its 2023–2024 grant cycle. One of these grants provided $500,000 in funding to Dr. David Lyden's team for a project focused on metastasis. The impact of such funding is often magnified. Building on an initial OSI grant, Baylor College of Medicine secured $4,500,000 in additional funding in 2024 to advance CAR-T therapy research. International collaborations are also being funded. In October 2024, one US–Israel Binational Science Foundation grant was awarded to a team including University of Vermont Cancer Center members to study osteosarcoma epigenetics. Wherein, government funding remains critical. In August 2024, Medical College of Georgia scientists received a five-year grant of $2,400,000 from the National Institute on Aging to study how stress hormones signal the skeleton. Philanthropic efforts are also significant, with over $4,600,000 raised from more than 1,000 donations in 2024 to support the OSI's vital mission. Diverse and Critical Applications Are Driving Widespread Adoption Across Multiple Fields The utility of human osteoblasts market extends across a wide spectrum of research and clinical applications. The dynamic interplay between 2 key cell types, osteoblasts and osteoclasts, is central to bone health, driving research into osteoporosis. In the laboratory, standardized protocols are essential. Human osteoblasts from PromoCell require approximately 3 weeks to show detectable mineralization in culture. Advanced 3D modeling is becoming a standard research tool. InSCREENex's immortalized human osteoblasts can form 3D "mini-bones" when cultured under specific conditions. Suppliers like PromoCell target 3 key application areas cell expansion, culture initiation, and differentiation. A 2024 study highlighted the use of 1 new 3D model based on human fetal osteoblasts to study osteocyte commitment. The clinical relevance is clear. The classic period for new bone formation after a tooth extraction, a process driven by osteoblasts, is 6-10 weeks. A 2025 study analyzed ion release from 3D printed scaffolds at 3 days, 7 days, and 15 days, key time points for osteoblast interaction. Quality Guarantees and Emerging Technologies Redefine the Global Human Osteoblasts Market The reliability of research outcomes depends on the quality of the underlying cell products. Suppliers in the market provide stringent quality guarantees. PromoCell guarantees >500,000 viable cells per cryovial after thawing. Innoprot similarly ensures >500,000 viable cells in each vial, cryopreserved at passage one, while Lonza guarantees ≥500,000 viable cells per ampule. For immortalized lines, Innoprot provides >1,000,000 viable cells per vial, and InSCREENex includes >0.5 million viable cells per vial. Longevity in culture is also specified. Innoprot guarantees 15 population doublings for its primary osteoblasts post-delivery. PromoCell recommends a split ratio of 1:3 to 1:6 for its primary cells. To support targeted research, PromoCell holds >100 HLA-typed cell donors in stock as of 2024, offering 4-digit high-resolution typing. The InSCREENex cell line was derived from a 63-year-old female donor. Concurrently, emerging technologies are creating new opportunities for the human osteoblasts market. Three key trends noted in the 2024 orthopedic biomaterials market are biodegradable materials, 3D printing, and nanotechnology. A September 2024 paper detailed 1 study using collagen-based 3D printed scaffolds to investigate osteoblast activity. A May 2024 publication described 1 new 3D in-vitro model using human fetal osteoblasts. A 2025 study utilized 2 cell lines to test 3D printed composite samples, using standards prepared from 1,000 mg/L stock solutions and a plating density of 10,000 cells/well for viability tests. Customize the Data Scope to Match Your Objectives: Strategic Alliances and Focused Regional Developments Indicate Strong Global Market Growth Corporate strategies and regional activities in 2024 and 2025 underscore a commitment to global expansion of the human osteoblasts market. On March 10, 2024, 1 major collaboration was announced between Athersys Inc. and Cerapedics Inc. to develop a novel osteoblast-based therapy. Service providers are also expanding. In 2024, Thermo Fisher launched its "Accelerator™ Drug Development" solutions, offering 360-degree support to biotech companies. Licensing agreements are expanding market access for key biologics. Bio-Thera Solutions entered into 1 exclusive licensing agreement on December 24, 2024, for its ustekinumab biosimilar. On the same day, GlycoNex announced 1 licensing agreement for its denosumab biosimilar, a therapy for bone loss. Regional market activities are intensifying. In 2024, 1 pivotal Phase 2 trial for osteosarcoma was opened in Barcelona, Spain. Stryker expanded with 1 new testing facility in India in February 2024. In May 2024, Sanofi announced 1 new partnership with OpenAI to accelerate R&D. The North American market saw the FDA grant 1 US approval to Pfizer's Beqvez on April 25, 2024. Europe showed activity with 1 approval by the UK's MHRA on January 15, 2025. The Asia-Pacific region is also growing, evidenced by 1 approval in Japan on January 7, 2025, for Biocon's ustekinumab. Global Human Osteoblasts Market Major Players: Athelas Bionova Scientific Cell Signaling Technology Corning EMD Millipore Invitrogen Lonza Merck Group NantKwest Promega R and D Systems ReproCELL Sigma-Aldrich Stemcell Technologies Thermo Fisher Scientific Other Prominent Players Key Market Segmentation: By Product Human Cell Culture Osteoblast Cell Lines By Application Traumatic Injuries Road Accidents Regeneration Surgeries Orthopedics Musculoskeletal and Spine Neurology By End user Hospitals Specialty Clinics Ambulatory Surgical Centers By Region North America Europe Asia Pacific Middle East & Africa South America Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Brokers risk falling behind as AI disruption accelerates
The majority of UK SMEs are comfortable with AI assessing their insurance needs and recommending the most suitable coverage options, according to GlobalData surveying. Meanwhile, AI-native insurance broker Meshed has secured backing from Aviva and other investors, with the aim of reshaping the commercial insurance market for SMEs. GlobalData's 2025 UK SME Insurance Survey has found that 64.5% of SMEs are comfortable, to some extent, with AI assessing their insurance needs and recommending the most suitable coverage options. Moreover, over a quarter of SMEs (26.7%) cited that they were extremely comfortable with this. How comfortable are you/would you be for an AI tool to do the following? 2025 Meanwhile, Meshed has raised £950,000 ($1.3m) in an oversubscribed pre-seed funding round to transform the commercial insurance market for SMEs. Investors included Haatch, Aviva via Founders Factory, the Exponential Science Foundation, and several angel backers. Meshed highlights that around 80% of UK SMEs remain underinsured, largely due to outdated brokerage practices and inefficient manual processes. By deploying AI-powered agents for quoting, data collection, and other routine tasks, the firm aims to cut administrative costs, reduce premiums, and enable brokers to focus more on client relationships and specialist advice. Yet, findings from our 2025 UK Commercial Insurance Broker Survey indicate that brokers may be underestimating the scale of disruption that AI could bring. Only 5.2% of brokers see AI as the biggest threat to their business, compared with 13.2% citing competition from other brokers and 11.2% from direct players. Moreover, adoption remains limited, with just 5.9% of brokers using AI-driven policy recommendation tools, while 78.6% report no plans to adopt them. Brokers should recognize that while AI may not seem like the greatest threat today, failing to adopt it could make it one tomorrow. By overlooking AI, brokers risk falling behind faster-moving competitors and losing relevance in a market where efficiency and digital capabilities increasingly drive client expectations. "Brokers risk falling behind as AI disruption accelerates" was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
